Skip to main content
Top
Published in: Clinical and Translational Oncology 6/2020

01-06-2020 | Research Article

Important prognostic factors in leiomyosarcoma survival: a National Cancer Database (NCDB) analysis

Authors: J. Gootee, N. Sioda, S. Aurit, C. Curtin, P. Silberstein

Published in: Clinical and Translational Oncology | Issue 6/2020

Login to get access

Abstract

Background

Leiomyosarcoma (LMS) is an aggressive, malignant mesenchymal tumor with characteristic smooth muscle lineage accounting for 10–20% of all soft tissue tumors. The goal of this study is to determine the impact of prognostic factors on leiomyosarcoma survival irrespective of primary anatomical site.

Methods

There were a total of 7154 patients with primary leiomyosarcoma identified and analyzed from the National Cancer Database. Descriptive statistics, median survival, and 5- and 10-year survival probabilities were calculated along with a Cox proportional hazard model to determine independent prognostic factors.

Results

In this study, females comprised 68.3% of the cohort with a median age of 58 years. The most common primary anatomical sites were the extremities followed by female reproductive organs, abdomen, pelvis, thorax or lung, and head or neck. Tumors localized in the female reproductive organs had the worst survival (5-year survival probability: 45.3%), while tumors localized in the extremities had the best survival outcomes (5-year survival probability: 73.4%). Surgery with adjuvant radiation yielded better outcomes compared to surgery alone (HR 0.82, 95% CI 0.74–0.91). Microscopic and macroscopic margins resulted in a 32% and a 134% increased risk in mortality, respectively, when compared to negative surgical margins (p < 0.0001).

Conclusion

This study showed a significantly higher risk of mortality associated with older patients, tumors localized to the female reproductive organs, African American patients, higher tumor stage, increased Charlson/Deyo scores, tumors treated with surgery alone without adjuvant radiation, and tumors with positive microscopic, macroscopic, or indeterminate surgical margins.
Literature
1.
go back to reference Serrano C, George S. Leiomyosarcoma. Hematol Oncol Clin N Am. 2013;27(5):957–74.CrossRef Serrano C, George S. Leiomyosarcoma. Hematol Oncol Clin N Am. 2013;27(5):957–74.CrossRef
2.
go back to reference Wang Z, Shi N, Naing A, et al. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016;5(12):3437–44.PubMedPubMedCentralCrossRef Wang Z, Shi N, Naing A, et al. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016;5(12):3437–44.PubMedPubMedCentralCrossRef
3.
go back to reference Dodd, Leslie G (2014) Atlas of soft tissue and bone pathology: with histologic, cytologic, and radiologic correlations Dodd, Leslie G (2014) Atlas of soft tissue and bone pathology: with histologic, cytologic, and radiologic correlations
4.
go back to reference Nusrath S, Vipin G, Narasimha R, Subramanyeshwar R, Sudha M. Primary pulmonary leiomyosarcoma: a case report. Indian J Thorac Cardiovasc Surg. 2018;34:76–9.CrossRef Nusrath S, Vipin G, Narasimha R, Subramanyeshwar R, Sudha M. Primary pulmonary leiomyosarcoma: a case report. Indian J Thorac Cardiovasc Surg. 2018;34:76–9.CrossRef
5.
go back to reference Alfarelos G, Campos M, Canelas A, Gonçalves M. Paratesticular leiomyosarcoma: a case report and review of the literature. Urol Case Rep. 2017;11.C:30–2.CrossRef Alfarelos G, Campos M, Canelas A, Gonçalves M. Paratesticular leiomyosarcoma: a case report and review of the literature. Urol Case Rep. 2017;11.C:30–2.CrossRef
6.
go back to reference Bathan A, Constantinidou A, Pollack S, Jones R. Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants. Curr Opin Oncol. 2013;24(4):384–9.CrossRef Bathan A, Constantinidou A, Pollack S, Jones R. Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants. Curr Opin Oncol. 2013;24(4):384–9.CrossRef
7.
go back to reference Rubenzik M, et al. Leiomyosarcoma. Mohs micrographic surgery. 2012nd ed. London: Springer; 2012. p. 279–285.CrossRef Rubenzik M, et al. Leiomyosarcoma. Mohs micrographic surgery. 2012nd ed. London: Springer; 2012. p. 279–285.CrossRef
8.
go back to reference Miettinen M, Fetsch JF. Evaluation of biological potential of smooth muscle tumours. Histopathology. 2006;48(1):97–105.PubMedCrossRef Miettinen M, Fetsch JF. Evaluation of biological potential of smooth muscle tumours. Histopathology. 2006;48(1):97–105.PubMedCrossRef
9.
go back to reference Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679–89.PubMedCrossRef Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679–89.PubMedCrossRef
10.
go back to reference Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914–26.PubMedCrossRef Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914–26.PubMedCrossRef
12.
go back to reference Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65(2):129–42.PubMedCrossRef Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65(2):129–42.PubMedCrossRef
13.
go back to reference Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol. 2017;145(1):208–16.PubMedCrossRef Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol. 2017;145(1):208–16.PubMedCrossRef
14.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.PubMedCrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.PubMedCrossRef
15.
go back to reference Seagle BL, Sobecki-Rausch J, Strohl AE, et al. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol. 2017;145(1):61–70.PubMedCrossRef Seagle BL, Sobecki-Rausch J, Strohl AE, et al. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol. 2017;145(1):61–70.PubMedCrossRef
16.
go back to reference Goldblum J, Enzinger F, Folpe A, Weiss S. Enzinger and Weiss's soft tissue tumors. 6th ed. Philadelphia: Saunders; 2014. Goldblum J, Enzinger F, Folpe A, Weiss S. Enzinger and Weiss's soft tissue tumors. 6th ed. Philadelphia: Saunders; 2014.
17.
go back to reference Kim H, Cho Y, Kim S, et al. Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. Int J Clin Oncol. 2015;20(6):1226–322.PubMedCrossRef Kim H, Cho Y, Kim S, et al. Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. Int J Clin Oncol. 2015;20(6):1226–322.PubMedCrossRef
19.
go back to reference Lusby K, Savannah K, Demicco B, et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution’s experience. Ann Surg Oncol. 2013;20(7):2364–72.PubMedPubMedCentralCrossRef Lusby K, Savannah K, Demicco B, et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution’s experience. Ann Surg Oncol. 2013;20(7):2364–72.PubMedPubMedCentralCrossRef
20.
go back to reference Eppsteiner RW, DeYoung BR, Milhem MM, Pagedar NA. Leiomyosarcoma of the head and neck: a population-based analysis. Arch Otolaryngol Head Neck Surg. 2011;137(9):921–4.PubMedPubMedCentralCrossRef Eppsteiner RW, DeYoung BR, Milhem MM, Pagedar NA. Leiomyosarcoma of the head and neck: a population-based analysis. Arch Otolaryngol Head Neck Surg. 2011;137(9):921–4.PubMedPubMedCentralCrossRef
21.
go back to reference Unal O, Oztop I, Yasar N, Urakci Z, et al. Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). J Thorac Oncol. 2015;6(1):85–90. Unal O, Oztop I, Yasar N, Urakci Z, et al. Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). J Thorac Oncol. 2015;6(1):85–90.
22.
go back to reference Pautier P, Genestie C, Rey A, et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer. 2000;88:1425–31.PubMedCrossRef Pautier P, Genestie C, Rey A, et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer. 2000;88:1425–31.PubMedCrossRef
23.
go back to reference Wong ML, Mcmurry TL, Schumacher JR, Hu CY, et al. Comorbidity assessment in the National Cancer Database for patients with surgically resected breast, colorectal, or lung cancer (AFT-01, -02, -03). J Oncol Pract. 2018;14(10):E631–e643643.PubMedPubMedCentralCrossRef Wong ML, Mcmurry TL, Schumacher JR, Hu CY, et al. Comorbidity assessment in the National Cancer Database for patients with surgically resected breast, colorectal, or lung cancer (AFT-01, -02, -03). J Oncol Pract. 2018;14(10):E631–e643643.PubMedPubMedCentralCrossRef
24.
go back to reference Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808–18.PubMedCrossRef Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808–18.PubMedCrossRef
25.
go back to reference Brennan M, Antonescu C, Maki R. Management of soft tissue sarcoma. New York: Springer; 2016.CrossRef Brennan M, Antonescu C, Maki R. Management of soft tissue sarcoma. New York: Springer; 2016.CrossRef
26.
go back to reference Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol. 2018;151(3):562–72.PubMedCrossRef Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol. 2018;151(3):562–72.PubMedCrossRef
27.
go back to reference Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199(5):536.e1–.e8.CrossRef Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199(5):536.e1–.e8.CrossRef
Metadata
Title
Important prognostic factors in leiomyosarcoma survival: a National Cancer Database (NCDB) analysis
Authors
J. Gootee
N. Sioda
S. Aurit
C. Curtin
P. Silberstein
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02196-7

Other articles of this Issue 6/2020

Clinical and Translational Oncology 6/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine